Plasma Pentraxin 3 Differentiates Nonalcoholic Steatohepatitis (NASH) from Non-NASH

Metabolic Syndrome and Related Disorders

Volumn 13, Issue 9, 2015, Pages 393-399

  Boga, Salih ^a,d   Koksal, Ali Riza ^a   Alkim, Huseyin ^a   Ozguven, Muveddet Banu Yilmaz ^a   Bayram, Mehmet ^a   Ergun, Meltem ^a   Sisman, Gurhan ^b   Tekin Neijmann, Sebnem ^c   Alkim, Canan ^a  

^a Department of Neurosurgery   (Turkey)

^b Istanbul Education and Research Hospital   (Turkey)

^c BAKIRKOY DR SADI KONUK TRAINING AND RESEARCH HOSPITAL   (Turkey)

^d YALE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PENTRAXIN 3; TUMOR NECROSIS FACTOR ALPHA; BIOLOGICAL MARKER; C REACTIVE PROTEIN; SERUM AMYLOID P;

ADULT; ALCOHOLIC FATTY LIVER; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; NONALCOHOLIC FATTY LIVER DISEASE ACTIVITY SCORE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; STEATOSIS; AREA UNDER THE CURVE; BIOPSY; BLOOD; CASE CONTROL STUDY; COMPARATIVE STUDY; DIFFERENTIAL DIAGNOSIS; FATTY LIVER; LIVER CIRRHOSIS; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PREDICTIVE VALUE; RECEIVER OPERATING CHARACTERISTIC; SEVERITY OF ILLNESS INDEX; UPREGULATION;

ADULT; AREA UNDER CURVE; BIOMARKERS; BIOPSY; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; DIAGNOSIS, DIFFERENTIAL; FATTY LIVER; FEMALE; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PREDICTIVE VALUE OF TESTS; ROC CURVE; SERUM AMYLOID P-COMPONENT; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 84946733444     PISSN: 15404196     EISSN: 15578518     Source Type: Journal    
DOI: 10.1089/met.2015.0046     Document Type: Article

References (29)

1. Tiniakos DG, Vos MB, Brunt EM. Nonalcoholic fatty liver disease: pathology and pathogenesis. Annu Rev Pathol 2010;5:145-171
2. Milic S, Stimac D. Nonalcoholic fatty liver disease/stea-tohepatitis: epidemiology, pathogenesis, clinical presentation and treatment. Dig Dis 2012;30:158-162
3. Bugianesi E, Leone N, Vanni E, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002; 123:134-140
4. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313-1321
5. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003;38: 1449-1457
6. Bottazzi B, Doni A, Garlanda C, et al. An integrated view of humoral innate immunity: pentraxins as a paradigm. Ann Rev Immunol 2010;28:157-183
7. Pepys M B, Hirschfield G M. C-reactive protein: a critical update. J Clin Invest 2003;111:1805-1812
8. Bottazzi B, Garlanda C, Cotena C, et al. The long pentraxin PTX3 as a prototypic humoral pattern recognition receptor: interplay with cellular innate immunity. Immunol Rev 2009; 227:9-18
9. Introna M, Alles VV, Castellano M, et al. Cloning of Mouse ptx3, a new member of the pentraxin gene family expressed at extrahepatic sites. Blood 1996;87:1862-1872
10. Wieckowska A, McCullough AJ, Feldstein AE. Non-invasive diagnosis and monitoring of nonalcoholic steato-hepatitis: present and future. Hepatology 2007;46:582-589
11. Targher G. Relationship between high-sensitivity C-reactive protein levels and liver histology in subjects with nonalcoholic fatty liver disease. J Hepatol 2006;45:879-881
12. Hanley AJ, Williams K, Festa A, et al. Liver markers and development of the metabolic syndrome: the insulin resistance atherosclerosis study. Diabetes 2005;54:3140-3147
13. Haukeland JW, Damas JK, Konopski Z, et al. Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. JHepatol 2006;44:1167-1174
14. Deniz T, Kizilgul M, Uzunlulu M, etal. Levels of Pentraxin 3 and relationship with disease activity in patients with anky-losing spondylitis. Acta Reumatol Port 2014;39:137-142
15. Zhang J, Shan L, Koussih L, et al. Pentraxin 3 (PTX3) expression in allergic asthmatic airways: role in airway smooth muscle migration and chemokine production. PLoS One 2012;7:1-9
16. Latini R, Maggioni AP, Peri G, et al. Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation 2004;110:2349-2354
17. Fazzini F, Peri G, Doni A, et al. PTX3 in small-vessel vascu-litides: an independent indicator of disease activity produced at sites of inflammation. Arthritis Rheum 2001;44:2841-2850
18. Muller B, Peri G, Doni A, et al. Circulating levels of the long pentraxin PTX3 correlate with severity of infection in critically ill patients. Crit Care Med 2001;29:1404-1407
19. Bastrup-Birk S, Skjoedt MO, Munthe-Fog L, et al. Pentraxin-3 serum levels are associated with disease severity and mortality in patients with systemic inflammatory response syndrome. PLoS One 2013;8:1-9
20. Suzuki S, Takeishi Y, Niizeki T, et al. Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure. Am Heart J 2008; 155:75-81
21. Morikawa S, Takabe W, Mataki C, et al. Global analysis of RNA expression profile in human vascular cells treated with statins. J Atheroscler Thromb 2004;11:62-72
22. Kleiner DE, Brunt EM, Van Natta M, et al. Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313-1321
23. Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003;37:917-923
24. Kang H, Greenson JK, Omo JT, et al. Metabolic syndrome is associated with greater histologic severity, high-ercarbohydrate, and lower fat diet in patients with NAFLD. Am J Gastroenterol 2006;101:2247-2253
25. Patel DA, Srinivasan SR, Xu JH, et al. Distribution and metabolic syndrome correlates of plasma Creactive protein in biracial (black-white) younger adults: the Bogalusa Heart Study. Metabolism 2006;55:699-705
26. Ridker PM, Buring JE, Cook NR, et al. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14719 initially healthy American women. Circulation 2003;107:391-397
27. Inoue K, Sugiyama A, Reid PC, et al. Establishment of a high sensitivity plasma assay for human pentraxin3 as a marker for unstable angina pectoris. Arterioscler Thromb Vasc Biol 2007;27:161-167
28. Hudzik B, Szkodzinski J, Pietka-Rzycka A, et al. Plasma pentraxin 3 may be a more sensitive marker of inflammatory response than high-sensitivity C-reactive protein after bare-metal stent compared to drug-eluting stent implantation. J Interferon Cytokine Res 2013;33:280-284
29. Peri G, Introna M, Corradi D, et al. PTX3, A prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation 2000;102:636-641